Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/35991
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Safipour, Z | - |
dc.contributor.author | van Der Zanden, R | - |
dc.contributor.author | VAN DEN BERGH, Joop | - |
dc.contributor.author | Janssen, P | - |
dc.contributor.author | Vestergaard, P | - |
dc.contributor.author | de Vries, F. | - |
dc.contributor.author | Driessen, JHM | - |
dc.date.accessioned | 2021-12-01T09:16:24Z | - |
dc.date.available | 2021-12-01T09:16:24Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2021-10-28T11:22:39Z | - |
dc.identifier.citation | OSTEOPOROSIS INTERNATIONAL, 33(3), p. 649-658 | - |
dc.identifier.issn | 0937-941X | - |
dc.identifier.uri | http://hdl.handle.net/1942/35991 | - |
dc.description.abstract | Oral glucocorticoids may increase major osteoporotic fracture risk (MOF) in myasthenia gravis patients. To assess this risk, we performed a case-control study including all Danish patients with a MOF between 1995 and 2011. We also pooled our data with data from another study. We found no increased risk. Osteoporosis prevention remains advisable. Purpose/introduction The prolonged use of high doses of oral glucocorticoids (GCs), a common treatment in patients with myasthenia gravis (MG), may increase major osteoporotic fracture (MOF) risk. Previous epidemiological studies did not exclusively focus on patients with MG or had relatively few GC-exposed MG patients. Aims were to evaluate the risk of MOF in MG patients using oral GCs in a large study population and to perform a pooled analysis with data from previous work. Methods A population-based case-control study (1995-2011) was conducted using the Danish National Health Service. Cases had sustained a MOF, and controls had not. All were aged >= 18 years. Multivariate conditional logistic regression estimated odds ratios (ORs) among MG patients using oral GCs versus non-users. Adjustments were made for comorbidities and comedications. In the pooled analysis, results were pooled by the use of generic inverse variance methods, assuming a random-effects model. Results We identified 376,858 cases and 376,858 controls. MOF risk was not elevated in MG patients currently using oral GCs compared to MG patients not on oral GCs (ORadj.: 1.26 (95% CI 0.68-2.33)). The use of the highest cumulative dose of oral GCs (>= 7 g) did not show an increased risk of MOF among MG patients (ORadj.: 2.00 (95% CI 0.90-4.44)). Our pooled analysis also showed no association between oral GC use and MOF risk. Conclusion This study showed that oral GC use in patients with MG was not associated with increased risk of MOF in our case-control study and pooled analysis. Osteoporosis prevention in MG patients based on clinical guidelines remains advisable. | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER LONDON LTD | - |
dc.rights | Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, | - |
dc.subject.other | Glucocorticoids; Fracture; Bone; Myasthenia gravis; Case-control study | - |
dc.title | The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 658 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 649 | - |
dc.identifier.volume | 33 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Driessen, JHM (corresponding author), Maastricht Univ, Dept Clin Pharm, Med Ctr, Maastricht, Netherlands.; Driessen, JHM (corresponding author), Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.; Driessen, JHM (corresponding author), Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands.; Driessen, JHM (corresponding author), Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands. | - |
dc.description.notes | annemariek.driessen@mumc.nl | - |
local.publisher.place | 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1007/s00198-021-06101-3 | - |
dc.identifier.isi | 000702791000001 | - |
dc.contributor.orcid | de Vries, Frank/0000-0003-3837-8319; van den Bergh, | - |
dc.contributor.orcid | Joop/0000-0003-3984-2232 | - |
dc.identifier.eissn | 1433-2965 | - |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
local.description.affiliation | [Safipour, Zohreh] Curacao Med Ctr, Dept Clin Pharm, Willemstad, Curacao. | - |
local.description.affiliation | [Safipour, Zohreh; van Der Zanden, Rogier; Janssen, Paddy; de Vries, Frank; Driessen, Johanna H. M.] Maastricht Univ, Dept Clin Pharm, Med Ctr, Maastricht, Netherlands. | - |
local.description.affiliation | [van den Bergh, Joop] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands. | - |
local.description.affiliation | [van den Bergh, Joop] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. | - |
local.description.affiliation | [van den Bergh, Joop] Viecuri Med Ctr, Dept Internal Med, Venlo, Netherlands. | - |
local.description.affiliation | [Janssen, Paddy] Viecuri Med Ctr, Dept Clin Pharm, Venlo, Netherlands. | - |
local.description.affiliation | [Vestergaard, Peter] Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark. | - |
local.description.affiliation | [Vestergaard, Peter] Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark. | - |
local.description.affiliation | [Vestergaard, Peter] Steno Diabet Ctr North Jutland, Aalborg, Denmark. | - |
local.description.affiliation | [de Vries, Frank] Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. | - |
local.description.affiliation | [de Vries, Frank; Driessen, Johanna H. M.] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands. | - |
local.description.affiliation | [Driessen, Johanna H. M.] Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands. | - |
local.description.affiliation | [Driessen, Johanna H. M.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands. | - |
local.uhasselt.international | yes | - |
item.contributor | Safipour, Z | - |
item.contributor | van Der Zanden, R | - |
item.contributor | VAN DEN BERGH, Joop | - |
item.contributor | Janssen, P | - |
item.contributor | Vestergaard, P | - |
item.contributor | de Vries, F. | - |
item.contributor | Driessen, JHM | - |
item.validation | ecoom 2022 | - |
item.fullcitation | Safipour, Z; van Der Zanden, R; VAN DEN BERGH, Joop; Janssen, P; Vestergaard, P; de Vries, F. & Driessen, JHM (2022) The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis. In: OSTEOPOROSIS INTERNATIONAL, 33(3), p. 649-658. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 0937-941X | - |
crisitem.journal.eissn | 1433-2965 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s00198-021-06101-3.pdf | Published version | 478.88 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
1
checked on Apr 22, 2024
Page view(s)
22
checked on Sep 7, 2022
Download(s)
10
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.